Table 3

Fractional anisotropy values for the cerebro-cerebellar tracts in HC and ALS-NEG and ALS-C9

Cerebro-cerebellar fractional anisotropy valuesEstimated marginal mean±SE for groupsStatistics
HC, n=110ALS-NEG, n=133ALS-C9, n=22Univariate effect sizeHC vs ALS-NEGHC vs ALS-C9
Left*FPCL1L0.453±0.0050.446±0.0050.439±0.005η2p=0.0640.9530.125
L1R0.465±0.0060.445±0.0060.432±0.006η2p=0.220 0.035 <0.001
PPCL1L0.445±0.0050.439±0.0050.430±0.005η2p=0.0731.0000.093
L1R0.452±0.0060.442±0.0060.423±0.006η2p=0.1430.763 0.006
TPCL1L0.353±0.0080.342±0.0080.343±0.008η2p=0.0190.9911.000
L1R0.338±0.0080.347±0.0080.335±0.008η2p=0.0201.0001.000
OPCL1L0.416±0.0080.410±0.0080.392±0.008η2p=0.0711.0000.117
L1R0.389±0.0100.362±0.0110.363±0.011η2p=0.0630.2260.256
DRTCL1L0.395±0.0050.399±0.0050.394±0.005η2p=0.0061.0001.000
L1R0.381±0.0070.345±0.0070.362±0.007η2p=0.173 0.002 0.179
Right†FPCR1R0.451±0.0050.444±0.0050.434±0.005η2p=0.0721.0001.000
R1L0.447±0.0050.436±0.0050.437±0.005η2p=0.0431.0001.000
PPCR1R0.439±0.0050.442±0.0060.425±0.006η2p=0.0751.0001.000
R1L0.426±0.0060.417±0.0060.425±0.006η2p=0.0211.0001.000
TPCR1R0.343±0.0070.348±0.0070.333±0.007η2p=0.0421.0001.000
R1L0.352±0.0080.347±0.0080.338±0.008η2p=0.0261.0001.000
OPCR1R0.409±0.0080.401±0.0090.401±0.009η2p=0.0101.0001.000
R1L0.392±0.0090.371±0.0090.377±0.009η2p=0.0491.0001.000
DRTCR1R0.390±0.0050.391±0.0050.387±0.005η2p=0.0051.0001.000
R1L0.356±0.0070.367±0.0070.365±0.007η2p=0.0201.0001.000
  • Estimated marginal mean±SE for fractional anisotropy adjusted for age and gender.

  • Post-hoc univariate comparisons across groups were only considered significant if the multivariate omnibus tests reached significance (left hemisphere).

  • Bold p values are significant at p<0.05 after Bonferroni correction for multiple comparisons.

  • Partial η2 effect size is interpreted as small (η2p=0.01), medium (η2p=0.06) or large (η2p=0.14).

  • *Wilks’ lambda=0.565; F=1.782; p=0.031; η2p=0.248.

  • †Wilks’ lambda=0.667; F=1.212; p=0.259; η2p=0.183.

  • ALS, amyotrophic lateral sclerosis; ALS-C9, patients who tested positive for GGGGCC repeat expansions in C9orf72; ALS-NEG, patients who tested negative for both ATXN2 and C9orf72; DRTC, dentate-rubro-thalamo-cortical; FPC, fronto-ponto-cerebellar; HC, healthy control; L1L, Left cerebellum to left cerebral hemisphere; L1R, Left cerebellum to right cerebral hemisphere; OPC, occipito-ponto-cerebellar; PPC, parieto-ponto-cerebellar; R1L, Right cerebellum to left cerebral hemisphere; R1R, Right cerebellum to right cerebral hemisphere; TPC, temporo-ponto-cerebellar.